{"id":"nuvaring","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. [See Contraindications (4) .] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS "],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Vaginitis","drugRate":"13.8%","severity":"common","organSystem":""},{"effect":"Headache (including migraine)","drugRate":"11.2%","severity":"common","organSystem":""},{"effect":"Mood changes (depression, mood swings, mood altered, depressed mood, affect lability)","drugRate":"6.4%","severity":"common","organSystem":""},{"effect":"Device-related events (expulsion/discomfort/foreign body sensation)","drugRate":"6.3%","severity":"common","organSystem":""},{"effect":"Nausea/vomiting","drugRate":"5.9%","severity":"common","organSystem":""},{"effect":"Vaginal discharge","drugRate":"5.7%","severity":"common","organSystem":""},{"effect":"Increased weight","drugRate":"4.9%","severity":"common","organSystem":""},{"effect":"Vaginal discomfort","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Breast pain/discomfort/tenderness","drugRate":"3.8%","severity":"common","organSystem":""},{"effect":"Dysmenorrhea","drugRate":"3.5%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"3.2%","severity":"common","organSystem":""},{"effect":"Acne","drugRate":"2.4%","severity":"common","organSystem":""},{"effect":"Decreased libido","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Deep vein thrombosis","drugRate":"","severity":"serious"},{"effect":"Stroke/cerebrovascular accident","drugRate":"","severity":"serious"},{"effect":"Arterial thromboembolism","drugRate":"","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Anxiety","drugRate":"","severity":"serious"},{"effect":"Cholelithiasis","drugRate":"","severity":"serious"},{"effect":"Vomiting","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Device breakage","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1531","moleculeType":"Small molecule","molecularWeight":"324.46"},"aliases":["Contraceptive vaginal ring","contraceptive vaginal ring"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"55eb60e3-6f4d-40a3-8ee6-e7fd2d0c7d97","title":"NUVARING (ETONOGESTREL AND ETHINYL ESTRADIOL) INSERT, EXTENDED RELEASE [ORGANON LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-27T23:57:56.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04257500","phase":"PHASE4","title":"Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS","status":"COMPLETED","sponsor":"Andrea Roe, MD, MPH","startDate":"2020-09-03","conditions":"Polycystic Ovary Syndrome","enrollment":22},{"nctId":"NCT02432404","phase":"PHASE4","title":"Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-03","conditions":"Bacterial Vaginosis","enrollment":81},{"nctId":"NCT05994599","phase":"PHASE1","title":"Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring","status":"COMPLETED","sponsor":"Evestra Inc.","startDate":"2023-07-29","conditions":"Healthy Women, Female, Contraception","enrollment":36},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT01709318","phase":"PHASE2","title":"A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-12","conditions":"Contraception","enrollment":666},{"nctId":"NCT01490190","phase":"PHASE4","title":"Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-12-26","conditions":"Contraception","enrollment":252},{"nctId":"NCT02275546","phase":"PHASE3","title":"Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2014-12-11","conditions":"Contraception: Optional Applicator for Insertion of Vaginal Ring","enrollment":164},{"nctId":"NCT05360576","phase":"PHASE2","title":"An Open-label, Randomized, 2-Period, Crossover, Pharmacokinetics Study","status":"COMPLETED","sponsor":"Lupin Research Inc","startDate":"2022-02-24","conditions":"Pregnancy Prevention","enrollment":40},{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT00635570","phase":"PHASE4","title":"Acceptability of the NuvaRing Among Students","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2008-07","conditions":"Birth Control Compliance","enrollment":273},{"nctId":"NCT02367833","phase":"PHASE4","title":"Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis","status":"COMPLETED","sponsor":"Penn State University","startDate":"2015-01","conditions":"Bone; Disorder, Development and Growth","enrollment":60},{"nctId":"NCT02404038","phase":"NA","title":"A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods","status":"UNKNOWN","sponsor":"Desmond Tutu HIV Centre","startDate":"2015-07","conditions":"HIV","enrollment":131},{"nctId":"NCT02445989","phase":"PHASE4","title":"Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Bacterial Vaginosis, HIV","enrollment":120},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT03120728","phase":"PHASE4","title":"Application for the Etonogestrel/Ethinyl Estradiol Ring","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2017-07-10","conditions":"Emergency Contraception, Healthy, Reproductive Age Women","enrollment":36},{"nctId":"NCT00369967","phase":"NA","title":"Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2007-02","conditions":"Contraception Desired","enrollment":48},{"nctId":"NCT02529683","phase":"NA","title":"Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-04","conditions":"Hormonal Contraception","enrollment":200},{"nctId":"NCT01638767","phase":"PHASE4","title":"NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles","status":"TERMINATED","sponsor":"Clinique Ovo","startDate":"2012-07","conditions":"Infertility","enrollment":7},{"nctId":"NCT00710606","phase":"NA","title":"Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®","status":"COMPLETED","sponsor":"Columbia University","startDate":"2008-06","conditions":"Pharmacokinetics","enrollment":40},{"nctId":"NCT01796613","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2013-06","conditions":"Contraception","enrollment":120},{"nctId":"NCT00524771","phase":"","title":"Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2007-09","conditions":"Contraception","enrollment":34100},{"nctId":"NCT00612508","phase":"NA","title":"Hormonal Contraception and Vaginal Health","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-05","conditions":"Contraceptive Usage, Vaginal Epithelial Disruption","enrollment":14},{"nctId":"NCT01298128","phase":"NA","title":"NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment","status":"TERMINATED","sponsor":"University of Toronto","startDate":"2006-02","conditions":"Infertility, In-vitro Fertilization","enrollment":70},{"nctId":"NCT01448291","phase":"PHASE4","title":"Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers","status":"UNKNOWN","sponsor":"Eastern Virginia Medical School","startDate":"2011-10","conditions":"Vaginosis, Bacterial","enrollment":30},{"nctId":"NCT01087879","phase":"NA","title":"The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2007-10","conditions":"Contraception","enrollment":45},{"nctId":"NCT01384331","phase":"PHASE4","title":"New Treatments for Troublesome Bleeding in Implanon Users","status":"UNKNOWN","sponsor":"Family Planning Association New South Wales","startDate":"2011-07","conditions":"Menstrual Problem","enrollment":200},{"nctId":"NCT00374387","phase":"NA","title":"Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2006-09","conditions":"Healthy","enrollment":150},{"nctId":"NCT01266759","phase":"NA","title":"Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2008-07","conditions":"Menorrhagia","enrollment":95},{"nctId":"NCT00565240","phase":"NA","title":"Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2007-11","conditions":"Ovarian Follicle","enrollment":41},{"nctId":"NCT00475553","phase":"NA","title":"Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®","status":"COMPLETED","sponsor":"Scott and White Hospital & Clinic","startDate":"2006-05","conditions":"Breakthrough Bleeding, Breakthrough Spotting","enrollment":75},{"nctId":"NCT00269620","phase":"PHASE4","title":"PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2005-06","conditions":"Contraception","enrollment":500}],"_emaApprovals":[],"_faersSignals":[{"count":3990,"reaction":"PULMONARY EMBOLISM"},{"count":2674,"reaction":"DEEP VEIN THROMBOSIS"},{"count":2232,"reaction":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION"},{"count":1353,"reaction":"DEVICE EXPULSION"},{"count":1189,"reaction":"NO ADVERSE EVENT"},{"count":1140,"reaction":"HEADACHE"},{"count":1134,"reaction":"METRORRHAGIA"},{"count":1018,"reaction":"INCORRECT DRUG ADMINISTRATION DURATION"},{"count":1006,"reaction":"NAUSEA"},{"count":949,"reaction":"UNINTENDED PREGNANCY"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20160219","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20050729","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20040204","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20021105","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20020205","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20020327","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20190508","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20181204","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20160930","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20240531","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20141031","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20071002","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20180212","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20130719","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20131004","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20040302","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20011003","type":"ORIG","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20020529","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20181204","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20170530","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20171204","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20220429","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20080429","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20170809","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20140618","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20061212","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"},{"date":"20131004","type":"SUPPL","sponsor":"ORGANON USA ORGANON","applicationNumber":"NDA021187"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":137,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Nuvaring","genericName":"Nuvaring","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}